Refine
Year of publication
- 2008 (87) (remove)
Document Type
- Doctoral Thesis (55)
- Article (31)
- Book (1)
Has Fulltext
- yes (87) (remove)
Is part of the Bibliography
- no (87)
Keywords
- RNS (3)
- Einzelpartikelelektronenmikroskopie (2)
- Fluoreszenzspektroskopie (2)
- HIV (2)
- Konformationsänderung (2)
- Ligand (Biochemie) (2)
- Molekulardynamik (2)
- Protein-Protein Interaktion (2)
- Signaltransduktion (2)
- Strukturaufklärung (2)
Institute
- Biochemie und Chemie (87) (remove)
Type I interferons (IFNs) signal for their diverse biological effects by binding a common receptor on target cells, composed of the two transmembrane IFNAR1 and IFNAR2 proteins. We have previously differentially enhanced the antiproliferative activity of IFN by increasing the weak binding affinity of IFN to IFNAR1. In this study, we further explored the affinity interdependencies between the two receptor subunits and the role of IFNAR1 in differential IFN activity. For this purpose, we generated a panel of mutations targeting the IFNAR2 binding site on the background of the IFNalpha2 YNS mutant, which increases the affinity to IFNAR1 by 60-fold, resulting in IFNAR2-to-IFNAR1 binding affinity ratios ranging from 1000:1 to 1:1000. Both the antiproliferative and antiviral potencies of the interferon mutants clearly correlated to the in situ binding IC(50) values, independently of the relative contributions of the individual receptors, thus relating to the integral lifetime of the complex. However, the antiproliferative potency correlated throughout the entire range of affinities, as well as with prolonged IFNAR1 receptor down-regulation, whereas the antiviral potency reached a maximum at binding affinities equivalent to that of wild-type IFNalpha2. Our data suggest that (i) the specific activity of interferon is related to the ternary complex binding affinity and not to affinity toward individual receptor components and (ii) although the antiviral pathway is strongly dependent on pSTAT1 activity, the cytostatic effect requires additional mechanisms that may involve IFNAR1 down-regulation. This differential interferon response is ultimately mediated through distinct gene expression profiling.
The neuronal adaptor protein Fe65 is involved in brain development, Alzheimer disease amyloid precursor protein (APP) signaling, and proteolytic processing of APP. It contains three protein-protein interaction domains, one WW domain, and a unique tandem array of phosphotyrosine-binding (PTB) domains. The N-terminal PTB domain (Fe65-PTB1) was shown to interact with a variety of proteins, including the low density lipoprotein receptor-related protein (LRP-1), the ApoEr2 receptor, and the histone acetyltransferase Tip60. We have determined the crystal structures of human Fe65-PTB1 in its apo- and in a phosphate-bound form at 2.2 and 2.7A resolution, respectively. The overall fold shows a PTB-typical pleckstrin homology domain superfold. Although Fe65-PTB1 has been classified on an evolutionary basis as a Dab-like PTB domain, it contains attributes of other PTB domain subfamilies. The phosphotyrosine-binding pocket resembles IRS-like PTB domains, and the bound phosphate occupies the binding site of the phosphotyrosine (Tyr(P)) within the canonical NPXpY recognition motif. In addition Fe65-PTB1 contains a loop insertion between helix alpha2 and strand beta2(alpha2/beta2 loop) similar to members of the Shc-like PTB domain subfamily. The structural comparison with the Dab1-PTB domain reveals a putative phospholipid-binding site opposite the peptide binding pocket. We suggest Fe65-PTB1 to interact with its target proteins involved in translocation and signaling of APP in a phosphorylation-dependent manner.
Cytotoxic T lymphocytes eliminate infected cells upon surface display of antigenic peptides on major histocompatibility complex I molecules. To promote immune evasion, UL49.5 of several varicelloviruses interferes with the pathway of major histocompatibility complex I antigen processing. However, the inhibition mechanism has not been elucidated yet. Within the macromolecular peptide-loading complex we identified the transporter associated with antigen processing (TAP1 and TAP2) as the prime target of UL49.5. Moreover, we determined the active oligomeric state and crucial elements of the viral factor. Remarkably, the last two residues of the cytosolic tail of UL49.5 are essential for endoplasmic reticulum (ER)-associated proteasomal degradation of TAP. However, this process strictly requires additional signaling of an upstream regulatory element in the ER lumenal domain of UL49.5. Within this new immune evasion mechanism, we show for the first time that additive elements of a small viral factor and their signaling across the ER membrane are essential for targeted degradation of a multi-subunit membrane complex.
Location and orientation of serotonin receptor 1a agonists in model and complex lipid membranes
(2008)
Magic angle spinning (MAS) NMR has been used to investigate the location and orientation of five serotonin receptor 1a agonists (serotonin, buspirone, quipazine, 8-OH-DPAT, and LY-163,165) in single component model lipid and brain lipid membranes. The agonist locations are probed by monitoring changes in the lipid proton chemical shifts and by MAS-assisted nuclear Overhauser enhancement spectroscopy, which indicates the orientation of the agonists with respect to the 1,2-dioleoyl-sn-glycero-3-phosphocholine lipids. In the single component bilayer, the membrane agonists are found predominantly in the top of the hydrophobic chain or in the glycerol region of the membrane. Most of the agonists orient approximately parallel to the membrane plane, with the exception of quipazine, whose piperazine ring is found in the glycerol region, whereas its benzene ring is located within the lipid hydrophobic chain. The location of the agonist in brain lipid membranes is similar to the 1,2-dioleoyl-sn-glycero-3-phosphocholine lipid bilayers; however, many of the agonists appear to locate close to the cholesterol in the membrane in preference to the phospholipids.
Mitochondrial complex I (NADH:ubiquinone oxidoreductase) undergoes reversible deactivation upon incubation at 30–37 °C. The active/deactive transition could play an important role in the regulation of complex I activity. It has been suggested recently that complex I may become modified by S-nitrosation under pathological conditions during hypoxia or when the nitric oxide:oxygen ratio increases. Apparently, a specific cysteine becomes accessible to chemical modification only in the deactive form of the enzyme. By selective fluorescence labeling and proteomic analysis, we have identified this residue as cysteine-39 of the mitochondrially encoded ND3 subunit of bovine heart mitochondria. Cysteine-39 is located in a loop connecting the first and second transmembrane helix of this highly hydrophobic subunit. We propose that this loop connects the ND3 subunit of the membrane arm with the PSST subunit of the peripheral arm of complex I, placing it in a region that is known to be critical for the catalytic mechanism of complex I. In fact, mutations in three positions of the loop were previously reported to cause Leigh syndrome with and without dystonia or progressive mitochondrial disease.
Chlamydia are obligate intracellular bacteria that cause variety of human diseases. Host cells infected with Chlamydia are protected against many different apoptotic stimuli. The induction of apoptosis resistance is thought to be an important immune escape mechanism allowing Chlamydia to replicate inside the host cell. Infection with C. trachomatis activates the Raf/MEK/ERK pathway and the PI3K/AKT pathway. Here we show that inhibition of these two pathways by chemical inhibitors sensitized C. trachomatis infected cells to granzyme B-mediated cell death. Infection leads to the Raf/MEK/ERK-mediated up-regulation and PI3K-dependent stabilization of the anti-apoptotic Bcl-2 family member Mcl-1. Consistently, interfering with Mcl-1 up-regulation sensitized infected cells for apoptosis induced via the TNF receptor, DNA damage, granzyme B and stress. Our data suggest that Mcl-1 up-regulation is primarily required to maintain apoptosis resistance in C. trachomatis-infected cells.
The increasing resistance of almost all pathogenic bacteria to antibiotics (multidrug resistance) causes a severe threat to public health. The mechanisms underlying multidrug resistance include the induced over expression of multidrug transporters which extrude a variety of lipophilic and toxic substrates in an energy dependent fashion through the membrane out of the cell. These proteins are found in all transporter families. The work described in this thesis is dedicated to drug-proton antiporters from the small multidrug resistance (SMR) family. These efflux pumps with just four transmembrane helices per monomer are so far the smallest transporters discovered. Their oligomeric state, topology, three dimensional structure, catalytic cycle and transport mechanism are still rather controversial. Therefore, the aim of this thesis was to directly address these questions for the small multidrug resistance proteins Halobacterium salinarium Hsmr and Escherichia coli (E. coli) EmrE using a number of biophysical methods such as NMR, transport assays, mass spectrometry and analytical ultracentrifugation. Especially the work on Hsmr has been challenging due to the halophilic nature of this protein. In Chapter 1, key questions and the most important biophysical techniques are introduced followed by Material and Methods in Chapter 2. Depending on experimental requirements, cell free or ‘classical’ in vivo expression has been used for this thesis. Cell free expression as an option for the production of small multidrug transporters has been explored in Chapter 3. It has been possible to produce the SMR family members Hsmr, EmrE, TBsmr and YdgF in vitro. The expression of Hsmr was investigated in more detail under different experimental conditions. Hsmr was either refolded from precipitate or maintained in a soluble form during expression in the presence of detergents and liposomes. Furthermore, amino acids for which no auxotrophic strains were available could be labelled successfully. This expression system has been also used for preparing labelled samples of EmrE as described in Chapter 9. In vivo in E. coli expression of Hsmr, as described in Chapter 4, provided large amounts of proteins if fermenter production was used. Uniform labelling and selective unlabelling with stable isotopes (13C, 15N) for NMR spectroscopy was achieved in vivo in a more efficient and cost effective manner than using the cell free approach for this protein. Hsmr could be purified successfully from both in vitro and in vivo expression media. Hsmr is expressed in vivo and in vitro with N-terminal formylation. The Nterminal formylation is unstable and Hsmr in the presence of low salt concentrations was amenable to N-terminal degradation. It was found that Hsmr shows longest stability in Fos-ß-choline® 12 and sodium dodecyl sulphate, but best reconstitution conditions were found, when dodecyl maltoside is used and exchanged with Escherichia coli lipids. A molar protein lipid ratio of 1 to 100, amenable to solid state nuclear magnetic resonance, has been achieved. Sample homogeneity was shown by freeze fracture electron microscopy. The oligomeric state of Hsmr in detergent has been assessed by SDS PAGE, blue native PAGE, size exclusion chromatography, analytical ultracentrifugation and laser induced liquid bead ion desorption mass spectrometry (LILBID) as described in Chapter 5. A concentration and detergent dependent monomer-oligomer equilibrium has been found by all methods. The activity of Hsmr under the sample preparation conditions used here was shown using radioactive and fluorescence binding as well as fluorescence and electrochemical transport assays (Chapter 6). For transport studies, a stable pH gradient was generated by co-reconstitution of Hsmr with bacteriorhodopsin and subsequent sample illumination. Based on the observed long term stability of Hsmr in Fos-ß-choline® 12 and sodium dodecyl sulphate, liquid state NMR experiments were attempted in order to assess the correct folding of Hsmr in detergent micelles (Chapter 7). 1D proton and 2D HSQC spectra of U-15N Hsmr revealed a poor spectral dispersion, low resolution and only a small number of peaks. These are at least partly due to long rotational correlation times of the large protein detergent complex. This problem has been overcome by applying solid-state NMR to Hsmr reconstituted into E. coli lipids (Chapter 8). Uniform 13C labelled samples were prepared and two dimensional proton-driven spin diffusion and double quantum-single quantum correlation spectra were acquired successfully. Unfortunately, the spectral resolution was not yet sufficient for further structural studies. Reasons for the observed linebroadening could be structural heterogeneity or molecular motions which interfere with the NMR timescale. Therefore, the protein mobility has been probed using static 2H solid state NMR on Ala-d3-Hsmr. It could be shown, that parts of Hsmr are remarkably mobile in the membrane and that this mobility can be limited by the addition of the substrate ethidium bromide. Ethidium bromide as well as tetraphenylphosphonium (TPP+) is typical multidrug transporter substrates. The membrane interaction of TPP+ in DMPC membranes has been resolved by 1H MAS NMR. It was found that it penetrates into the interface region of the lipid bilayers and therefore behaves like many other transporter substrates adding to the hypothesis that the membrane could act as a pre-sorting filter. Finally, Chapter 9 is dedicated to the characterisation of the essential and highly conserved residue Glu-14 in EmrE by solid-state NMR. In order to avoid spectral overlap, the single Glu EmrE E25A mutant was chosen instead of the wildtype. The protein has been produced in vitro to take advantage of reduced isotope scrambling in the cell free expression system as verified by analytical NMR spectroscopy. Correct labelling of EmrE was tested by MALDI-TOF and solid-state NMR. The dimeric state of DDM solubilised EmrE has been probed by LILBID. The labelled protein was reconstituted into E. coli lipids to ensure a native membrane environment. Activity was determined by measuring ethidium bromide transport. Freeze fracture EM revealed very homogeneous protein incorporation even after many days of MAS NMR experiments. 2D 13C double quantum filtered experiments were used to obtain chemical shift and lineshape information of Glu-14 in EmrE. Two distinct populations were found with backbone chemical shift differences of 4 - 6 ppm which change upon substrate binding. These findings indicate a structural asymmetry at the assumed dimerisation interface and are discussed in the context of a model for shared substrate/proton binding. These studies represent the first successful use of cell free expression to prepare labelled membrane proteins for solid-state NMR and allow for the first time an NMR insight into the binding pocket of a multidrug efflux pump.
Cytochrome c oxidase (CcO), also called Complex IV of the aerobic respiratory chain, is located in the plasma membrane of prokaryotes and in the inner mitochondrial membrane of eukaryotes. The redox energy of dioxygen reduction is used to translocate protons across the membrane resulting in an electrochemical proton gradient. The generated proton gradient is exploited by the adenosine-5’-triphosphate synthase. In this work, bacterial four-subunit aa3-Type CcO from Paracoccus denitrificans (ATCC 13543, 4 SU-wt ATCC CcO) was used for analyses. 1) The recombinant homologously produced 4 SU-wt CcO (4 SU-wt rec CcO) was functionally compared with the native 4 SU-wt ATCC CcO. The 4 SU-wt rec CcO showed functional deficiencies as determined by UV-vis spectroscopy and electron paramagnetic resonance (EPR) studies. Total X-ray Reflection Fluorescence measurements show in both wild type CcOs the same ratio of the redoxactive Fe and Cu (2 Fe : 3 Cu) indicating full complement of the functional metals. If CcO contains only subunit I and II, it loses its functional integrity during continuous turnover activity. The importance of subunit III for integrity of CcO was demonstrated using 2 SU-wt rec CcO. Crystallisation trials of suicide inactivated 2 SU-wt rec CcOs have been ineffective using standard crystallisation conditions. Crystals of active 2 SU-wt rec CcO (positive control) have been obtained under these conditions and this result indicates possible structural changes in suicide inactivated 2 SU-wt rec CcO. The structure of active 2 SU-wt rec CcO was determined to 2.25 Å resolution. 2) Terminal oxidases require four electrons for the cleavage of the dioxygen bond (O=O). In general, the catalytic cycle of CcO is described by the electron input and thus by the different redox states of the metal centres: the O, E, R, P and F state. The two-electron reduced R intermediate is able to donate four electrons for dioxygen reduction forming the P state. The P intermediate is an oxoferryl state implying the lack of an electron for the R -> P transition, because the metal centres can only provide three electrons (Fe+II forms Fe+IV and Cu+II forms Cu+I). The P state, where the dioxygen bond is already broken, shows an oxoferryl state (FeIV=O2-) and a nearby tyrosine is proposed to form a tyrosyl radical representing the donor of the missing electron. H2O2-induced artificial intermediates provide the opportunity to investigated different catalytic intermediates in detail. Mixing equimolar amounts of H2O2 to CcO in the O state induces the "two-electron" reduced PH state at high pH and the electronically equal "two-electron" reduced F• H state at low pH. The addition of an excess amount of H2O2 leads to the three-electron reduced FH state. Functional studies using the 4 SU-wt ATCC CcO have demonstrated a bound peroxide (O- - O-) intermediate during the catalytic cycle. Using EPR it was previously shown that Y167 hosts a radical species in PH/F• H state which suggests that Y167 could provide this "missing electron". While X-ray structural models of CcO and Fourier-transformed infrared (FTIR) measurements of oxygenated ("pulsed") 4 SU-wt ATCC CcO suggest a bound peroxide in the O state, UV-vis and EPR spectroscopic studies indicate that other intermediates may also contain such peroxide species. Equimolar and excess amounts of H2O2 induce the PH/F• H and FH states, respectively and catalase treatment of the FH state leads, contrary to the natural direction of the catalytic cycle, to the apparent transition of the FH -> PH/F• H states, which is accompanied by reappearance of an EPR signal from the Y167• radical. The novel PFH/F• FH states are presented here and we postulate that the FH state hosts a superoxide (or peroxide) adduct at CuB in the binuclear site. In addition, the novel P10 state is also introduced having a maximum at lambda = 612 nm in the difference absorption spectrum (minus the O state). The P10 state is induced by mixing CcO in the O state with a pH 10 buffer. This pH 10 induced state resembles standard P states such as PCO, PH and PR. However, the P10 state evolves out of the O state without addition of reduction equivalents. Using EPR spectroscopy it was shown that Y167 hosts a radical species in the P10 state such as in the PH state. In summary, all functional data presented here provide evidence for a peroxide bound during the O state. Finally, a new model for the natural catalytic cycle is proposed. If the O state contains a peroxide, it is also likely that the E and R state contain this species. Even the oxoferryl intermediates P and F states may complex a peroxide at CuB in the binuclear site. 3) The amino acid residue Y167, which hosts the radical in the PH/F•H states, is not directly part of the binuclear site of CcO. For identification of the primary electron donor, two tryptophan variants of CcO, W272F and W164F, which are located nearby the binuclear site, were produced. Evidence is provided that W272 is a kinetically fast electron donor for the O2 molecule. The electron is replenished by Y167, or probably by Y280 in the natural cycle. The Y167 radical is detectable by EPR spectroscopy after treatment with equimolar amounts of H2O2 in the active variant W164F, but is absent in the inactive variant W272F. 4) CcO contains two proton conducting pathways, the D- and the K-pathway. Proteoliposomes of the variants H28A and D30N, mutations located at the entrance of the D-pathway, both show the identical proton pumping activity as the 4 SU-wt rec CcO (pumped H+/e- = 1). The variant N113D shows abolished proton pumping (pumped H+/e- = 0), but a relative high cytochrome c oxidation activity (63 %). G196D displays no cytochrome c oxidation and proton pumping activity. Overall, the addition or removal of a negative charge within the D-pathway such as in D124N, N131D, N113D and G196D leads to a decoupled phenotype indicating the high degree of electrostatic coupling in CcO.
Untersuchungen zum Target und Wirkmechanismus der eNOS-Transkriptionsverstärker AVE9488 und AVE3085
(2008)
Die Substanzen AVE9488 und AVE3085 der neuen chemischen Klasse der eNOS-Transkriptionsverstärker führen zu einer signifikanten Aktivierung des eNOSPromotors, die in vitro und in vivo in einer Erhöhung der eNOS-Expression auf mRNAund Proteinebene resultiert. Als Folge davon kommt es zu einer signifikant gesteigerten Synthese von bioverfügbarem Stickstoffmonoxid (NO). Dieser Effekt führt in Kombination mit einer ebenfalls beobachteten Normalisierung der eNOS-Entkopplung zu einer deutlichen antiatherosklerotischen Wirkung in ApoE-Knockout-Mäusen. AVE9488 und AVE3085 wurden initial durch eine phänotypische Reihentestung chemischer Bibliotheken in einer stabilen eNOS-Promotor-Reporter-Endothelzelllinie identifiziert. Daher waren bis zum heutigen Zeitpunkt molekulare Targets und ihre Wirkweise unbekannt. Das Ziel der vorliegenden Arbeit bestand daher darin, Targetproteine der eNOS-Transkriptionsverstärker zu identifizieren, zu validieren und Hinweise auf den zugehörigen Wirkmechanismus zu sammeln. Zur Identifizierung potenzieller Zielproteine wurden zwei unterschiedliche Strategien verfolgt. In einem genomischen Ansatz sollten einzelne, für die Aktivierung des eNOSPromotors durch AVE9488 und AVE3085 essentielle Transkriptionsfaktoren identifiziert werden. Eine in silico-Analyse des für die Substanzwirkung notwendigen 300bp-Promotorbereichs vor Transkriptionsstart auf konservierte Transkriptionsfaktor-Bindemotive ergab potenzielle Bindungsstellen für insgesamt 105 Transkriptionsfaktoren. In Gel-Retardierungsexperimenten mit Oligonukleotiden, die aufbauend auf der bioinformatischen Analyse die konservierten cis-Elemente in diesem Sequenzbereich abdeckten, und Kernextrakten aus Endothelzellen, die mit AVE9488 behandelt worden waren, konnte eine Abschwächung der DNA-Protein-Komplexbildung beobachtet werden. Diese Effekte konnten jedoch mit dieser Technologie aufgrund der hohen Anzahl möglicher bindender Transkriptionsfaktoren nicht auf einzelne eingeengt werden. Im Folgenden wurden daher einzelne Transkriptionsfaktoren ausgewählt, die eine nachgewiesene Rolle bei der Regulation der eNOS-Transkription besitzen, und auf ihre Bedeutung bei der Substanz- ermittelten eNOS-Promotoraktivierung untersucht. Nach Ausschaltung durch siRNA von Sp1, GATA-2, Ets-1, MAZ und PATZ1 im eNOS-Transkriptionstest konnten bei Sp1, GATA-2 und MAZ lediglich eine Erniedrigung der basalen eNOS-Promotoraktivitätfestgestellt werden. Da die Substanz-induzierte eNOS-Transkriptionserhöhung bei keinem der untersuchten Transkriptionsfaktoren beeinflusst wurde, scheinen diese Proteine bei diesem Prozess keine Rolle zu spielen. Als zweite Strategie kamen Proteomik-Techniken zur Identifizierung möglicher Targetprot eine durch ihre direkte biochemische Affinität zum Pharmakophor der eNOS-Transkriptionsverstärker zum Einsatz. Durch die chromatographische Anreicherung bindender Proteine aus Endothelzelllysaten an spezifischen Affinitätsmaterialien und der Markierung rekombinanter, humaner Proteine auf Protein-Mikroarrays mit Biotinmarkierten eNOS-Transkriptionsverstärkern konnte eine Gesamtliste mit insgesamt 18 potenziellen Targetkandidaten ermittelt werden. Die weitere zelluläre Validierung dieser Kandidaten erfolgte durch ihre siRNA-vermittelte Ausschaltung im eNOS-Transkriptionstest. Innerhalb aller potenziellen Targets konnte nur nach Ausschalten von Häm-bindenden Protein 1 (HEBP1) der eNOS-Promotor durch AVE3085 nur noch signifikant abgeschwächt gegenüber der Kontrolle aktiviert werden. Dieses Protein stellte somit den einzigen Targetkandidaten dar, der bei der Aktivierung des eNOS-Promotors eine Rolle zu spielen scheint. Nach rekombinanter Expression des humanen HEBP1 konnte die Bindung der eNOS-Transkriptionsverstärker an dieses Protein durch zwei unabhängige biochemische Methoden konfirmiert werden. Bei Messungen der Tryptophanfluoreszenz des HEBP1 konnte der eNOS-Transkriptionsverstärker 9257 den Liganden Hämin, der eine Quenchung der Fluoreszenz bewirkt, aus der Bindung verdrängen. Weiterhin konnte mit Hilfe einer Fluoreszenz-markierten eNOS-Substanz ihre direkte Bindung an das HEBP1 durch Messung der Fluoreszenzpolarisation nachgewiesen und ein KD-Wert von 11,7μM ermittelt werden. Abschließend konnte in ersten Untersuchungen der Hebp1-Expression in einem Herz-Kreislauf-relevanten Tiermodell für chronische Herzinsuffizienz nach Myokardinfarkt die differentielle Hochregulation des Hebp1-Gens um den Faktor 2,5 unter pathologischen Bedingungen nachgewiesen werden, die jedoch nicht durch die Behandlung mit AVE3085 beeinflusst wurde.